Bone marrow mesenchymal cells for haemophilia A gene therapy using retroviral vectors with modified long-terminal repeats

Haemophilia

Volumn 9, Issue 1, 2003, Pages 94-103

  Van Damme, A ^a   Chuah, M K L ^a   Dell 'Accio, F ^b   De Barri, C ^b   Luyten, F ^b   Collen, D ^a   Vandendriessche, Thierry ^a  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Bone Marrow Stroma; ex vivo gene therapy; Factor VIII; Haemophilia; Mesenchymal cells; Retroviral vector

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 8; CIS ACTING ELEMENT; COMPLEMENTARY DNA; DNA; MESSENGER RNA; MYELOABLATIVE AGENT; RETROVIRUS VECTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SP1;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ARTICLE; BONE MARROW CELL; CELL LINEAGE; CELL POPULATION; CELL RENEWAL; CELL TYPE; CONTROLLED STUDY; DNA MODIFICATION; EMBRYO CELL; GENE EXPRESSION; GENE THERAPY; GENETIC CODE; GENETIC TRANSCRIPTION; GENETIC TRANSDUCTION; HEMATOPOIETIC STEM CELL; HEMOPHILIA A; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LONG TERMINAL REPEAT; MESENCHYME CELL; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SCID MOUSE; SCORING SYSTEM; STEM CELL; TARGET CELL; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; XENOGRAFT;

EID: 0037276158     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.2003.00709.x     Document Type: Article

References (39)

1. Chao H, Mao L, Bruce AT et al. Sustained expression of human factor VIII in mice using a parvovirus-based vector. Blood 2000; 95: 1594-9.
2. Chao H, Walsh CE. Induction of tolerance to human factor VIII in mice. Blood 2001; 97: 3311-2.
3. Andrews JL, Kadan MJ, Gorziglia MI et al. Generation and characterization of e1/e2a/e3/e4-deficient adenoviral vectors encoding human factor VIII. Mol Ther 2001; 3: 329-36.
4. Balague C, Zhou J, Dai Y et al. Sustained high-level expression of full-length human factor VIII and restoration of clotting activity in hemophilic mice using a minimal adenovirus vector. Blood 2000; 95: 820-8.
5. Zhang WW, Josephs SF, Zhou J et al. Development and application of a minimal-adenoviral vector system for gene therapy of hemophilia A. Thromb Haemost 1999; 82: 562-71.
6. Park F, Ohashi K, Kay MA. Therapeutic levels of human factor VIII and IX using HIV-1-based lentiviral vectors in mouse liver. Blood 2000; 96: 1173-6.
7. Roth DA, Tawa NE Jr, O'Brien JM et al. Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A. N Engl J Med 2001; 344: 1735-42.
8. Evans GL, Morgan RA. Genetic induction of immune tolerance to human clotting factor VIII in a mouse model for hemophilia A. Proc Natl Acad Sci USA 1998; 95: 5734-39.
9. Hoeben RC, Einerhand MP, Briet E et al. Toward gene therapy in haemophilia A: retrovirus-mediated transfer of a factor VIII gene into murine haematopoietic progenitor cells. Thromb Haemost 1992; 67; 341-5.
10. Van Damme A, Vanden Driessche T, Collen D et al. Bone marrow stromal cells as targets for gene therapy. Curr Gene Ther 2002; 2: 195-209.
11. Jiang Y, Jahagirdar BN, Reinhardt RL et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002; 418: 41-9.
12. Reyes M, Lund T, Lenvik T et al. Purification and ex vivo expansion of postnatal human marrow mesodermal progenitor cells. Blood 2001; 98: 2615-25.
13. Chuah MKL, Brems H, Vanslembrouck V et al. Bone marrow stromal cells as targets for gene therapy of hemophilia A. Hum Gene Ther 1998; 9: 353-65.
14. Drize NJ, Surin VL, Gan OI et al. Gene therapy model for stromal precursor cells of hematopoietic microenvironment. Leukemia 1992; 6: 174S-75S.
15. Li KJ, Dilber MS, Abedi MR et al. Retroviral-mediated gene transfer into human bone marrow stromal cells: studies of efficiency and in vivo survival in SCID mice. Eur J Haematol 1995; 55: 302-6.
16. Nolta JA, Hanley MB, Kohn DB. Sustained human hematopoiesis in immunodeficient mice by cotransplantation of marrow stroma expressing human interluekin-3: analysis of gene transduction of long-lived progenitors. Blood 1994; 83: 3041-51.
17. Horwitz EM, Gordon PL, Koo WK et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc Natl Acad Sci USA 2002; 99: 8932-7.
18. Challita P-M, Kohn DB. Lack of expression from a retroviral vector after transduction of murine hematopoietic stem cells is associated with methylation in vivo. Proc Natl Acad Sci USA 1994; 91: 2567-71.
19. Challita P-M, Skelton D, El-Khoueiry A et al. Multiple modifications in cis elements of the long terminal repeat of retroviral vectors lead to increased expression and decreased DNA methylation in embryonic carcinoma cells. J Virol 1995; 69: 748-55.
20. Robbins PB, Yu X-J, Skelton D et al. Increased probability of expression from modified retroviral vectors in embryonal stem cells and embryonal carcinoma cells. J Virol 1997; 71: 9466-74.
21. Robbins PB, Skelton DC, Yu X-J et al. Consistent, persistent expression from modified retroviral vectors in murine hematopoietic stem cells. Proc Natl Acad Sci USA 1998; 95: 10182-87.
22. Chuah MKL, Damme AV, Zwinnen H et al. Long-term persistence of human bone marrow stromal cells transduced with factor VIII-retroviral vectors and production of therapeutic levels of human factor VIII in nonmyeloablated immunodeficient mice. Hum Gene Ther 2000; 11: 729-38.
23. De Bari C, Dell'Accio F, Tylzanowski P et al. Multipotent mesenchymal stem cells from adult human synovial membrane. Arthritis Rheum 2001; 44: 1928-42.
24. Chuah MKL, VandenDriessche T, Morgan RA. Development and analysis of retroviral vectors expressing human factor VIII as a potential gene therapy for hemophilia A. Hum Gene Ther 1995; 6: 1363-77.
25. VandenDriessche T, Vanslembrouck V, Goovaerts I et al. Long-term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in factor VIII-deficient mice. Proc Natl Acad Sci USA 1999; 96: 10379-84.
26. Clark LN, Koehler U, Ward DC et al. Analysis of the organisation and localisation of the FSHD-associated tandem array in primates: implications for the origin and evolution of the 3.3 kb repeat family. Chromosoma 1996; 105: 180-9.
27. Prince VE, Rigby PWJ. Derivatives of Moloney Murine Sarcoma Virus capable of being transcribed in embryonal carcinoma stem cells have gained a functional Sp1 binding site. J Virol 1991; 65: 1803-11.
28. Flanagan JR, Becker KG, Ennist DL et al. Cloning of a negative transcription factor that binds to the upstream conserved region of Moloney murine leukemia virus. Mol Cell Biol 1992; 12: 38-44.
29. Flanagan JR, Krieg AM, Max EE et al. Negative control region at the 5′ end of murine leukemia virus long terminal repeats. Mol Cell Biol 1989; 9: 739-46.
30. Grez M, Zörnig M, Nowock J et al. A single point mutation activates the moloney murine leukemia virus long terminal repeat in embryonal stem cells. J Virol 1991; 65: 4691-98.
31. Shultz LD, Schweitzer PA, Christianson SW et al. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J Immumol 1995; 154: 180-91.
32. Garcia-Martin C, Chuah MK, Van Damme A et al. Therapeutic levels of human Factor VIII in mice implanted with encapsulated cells: potential for gene therapy of haemophilia A. J Gene Med 2002; 4: 215-23.
33. Fallaux FJ, Hoeben RC, Cramer SJ et al. The human clotting factor VIII cDNA contains an automatically replicating sequence consensus- and matrix attachment region-like sequence that binds a nuclear factor, represses heterologous gene expression and mediates the transcriptional effects of sodium butyrate. Mol Cell Biol 1996; 16: 4264-72.
34. Hoeben RC, Fallaux FJ, Cramer SJ et al. Expression of the blood-clotting factor-VIII cDNA is repressed by a transcriptional silencer located in its coding region. Blood 1995; 85: 2447-54.
35. Koeberl DD, Halbert CL, Krumm A et al. Sequences within the coding regions of clotting factor VIII and CFTR block transcriptional elongation. Hum Gene Ther 1995; 6: 469-79,
36. Lynch CM, Israel DI, Kaufman RJ et al. Sequences in the coding region of clotting factor VIII act as dominant inhibitors of RNA accumulation and protein production. Hum Gene Ther 1993; 4: 259-72.
37. Dwarki VJ, Belloni P, Nijar T et al. Gene therapy for hemophilia A: production of therapeutic levels of human factor VIII in vivo in mice. Proc Natl Acad Sci USA 1995; 92: 1023-27.
38. Do H, Healey JF, Waller EK et al. Expression of factor VIII by murine liver sinusoidal endothelial cells. J Biol Chem 1999; 274: 19587-92.
39. Lin Y, Chang L, Solovey A et al. Use of blood outgrowth endothelial cells for gene therapy for hemophilia A. Blood 2002; 99: 457-62.